Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm
Nucleos(t)ide analogues (NA) are widely used to treat hepatitis B virus (HBV) infection, but they cannot eradicate the virus and treatment duration can be lifelong if the endpoint is set at seroclearance of the hepatitis B surface antigen (HBsAg). As an alternative strategy, finite NA therapy withou...
Kaydedildi:
| Asıl Yazarlar: | , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Korean Association for the Study of the Liver
2023-10-01
|
| Seri Bilgileri: | Clinical and Molecular Hepatology |
| Konular: | |
| Online Erişim: | http://e-cmh.org/upload/pdf/cmh-2022-0420.pdf |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|